Struggling Ambrilia shutters facility, sheds jobs

Struggling to stay afloat, Canada's Ambrilia Biopharma is jettisoning its manufacturing facility and shedding jobs. It is also planning to move out of its offices in Montreal and find less expensive digs. Ambrilia waved a red flag to investors last summer when the developer said it didn't have enough cash on hand to meet its obligations. The biotech says that it will terminate its current lease at the end of the month. Ambrilia's shares closed yesterday at 3 cents. Release | Story

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.